Independent directory Public ClinicalTrials.gov records United States
Clear filters
ClinicalTrials.gov public records Last synced Jul 23, 2026, 12:19 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 922 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Conditions
Influenza
Interventions
GSK2340274A, GSK2340273A
Biological
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
4,048 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2011
U.S. locations
25
States / cities
Mesa, Arizona • Phoenix, Arizona • Los Angeles, California + 21 more
Conditions
Influenza
Interventions
CAIV-T, TIV, Placebo
Biological
Lead sponsor
MedImmune LLC
Industry
Eligibility
18 Years to 65 Years
Enrollment
31 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2001
U.S. locations
1
States / cities
Stamford, Connecticut
Recruiting Phase 2 Interventional Accepts healthy volunteers

A Study to Learn About mRNA Vaccines Against Influenza in Adults

NCT07431853
Conditions
Healthy Adults
Interventions
Vaccine Candidate #1, Vaccine Candidate #2, Vaccine Candidate #3, Vaccine Candidate #4, Vaccine Candidate #5, Vaccine Candidate #6, TIV1 or TIV2
Biological
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
770 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2027
U.S. locations
15
States / cities
Mobile, Alabama • Walnut Creek, California • Milford, Connecticut + 12 more
Terminated No phase listed Observational Accepts healthy volunteers

NK Cell Mediated Influenza Immunity During Pregnancy

NCT03196245
Conditions
Pregnancy Related, Influenza, Human
Interventions
There is no intervention.
Other
Lead sponsor
Stanford University
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
94 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2019
U.S. locations
1
States / cities
Stanford, California
Conditions
Influenza
Interventions
Fluarix, GSK Biologicals Influenza Vaccine GSK576389A
Biological
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
1,252 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2008
U.S. locations
9
States / cities
Clearwater, Florida • Coral Gables, Florida • Milford, Massachusetts + 6 more
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers

Open Label Evaluation of H5N1 Vaccine at Vaccine Manufacturing Facilities

NCT00311649
Conditions
Influenza
Interventions
Inactivated Influenza A Vaccine A/H5N1
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
83 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2006
U.S. locations
1
States / cities
Swiftwater, Pennsylvania
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers

H5 Adult - Chiron Study of Bird Flu Vaccine

NCT00280033
Conditions
Influenza
Interventions
Aluminum hydroxide, Inactivated Influenza A/H5N1 Vaccine (Chiron), MF-59, Placebo
Biological · Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 64 Years
Enrollment
394 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006
U.S. locations
4
States / cities
Stanford, California • St Louis, Missouri • Cincinnati, Ohio + 1 more
Conditions
Immunization; Infection, Transplantation Infection, Influenza
Interventions
Standard Dose Quadrivalent Inactivated Influenza Vaccine, High Dose Quadrivalent Inactivated Influenza Vaccine
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
3 Years to 17 Years
Enrollment
312 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
8
States / cities
Stanford, California • Atlanta, Georgia • Chicago, Illinois + 5 more
Completed Phase 2 Interventional Accepts healthy volunteers

H7N9 Boost in Healthy Adults

NCT02586792
Conditions
Influenza
Interventions
Monovalent influenza A/H7N9 virus vaccine
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
19 Years to 50 Years
Enrollment
27 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016
U.S. locations
1
States / cities
Houston, Texas
Conditions
SARS-CoV-2, Influenza
Interventions
mRNA-1073, mRNA-1010, mRNA-1273, Placebo
Biological
Lead sponsor
ModernaTX, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
550 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022
U.S. locations
14
States / cities
Hollywood, Florida • Peoria, Illinois • Sioux City, Iowa + 9 more
Conditions
Influenza Immunization
Interventions
Pandemic flu H5 mRNA vaccine, Placebo
Biological · Other
Lead sponsor
Sanofi Pasteur, a Sanofi Company
Industry
Eligibility
18 Years and older
Enrollment
276 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2026
U.S. locations
14
States / cities
La Mesa, California • DeLand, Florida • Lakeland, Florida + 11 more
Withdrawn Phase 1 Interventional Accepts healthy volunteers

Pharma-Pen (Formerly Innoject) Auto-injectory TIV

NCT00335855
Conditions
Influenza
Interventions
Auto-injector for IM/SC vaccine administration
Device
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 50 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
Ends 2006
U.S. locations
1
States / cities
Richmond, Virginia
Conditions
Viral Lung Infection and Acute Respiratory Failure
Interventions
Tozorakimab, Placebo
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years and older
Enrollment
3,527 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
72
States / cities
Mobile, Alabama • Phoenix, Arizona • Tucson, Arizona + 65 more
Terminated No phase listed Observational Accepts healthy volunteers

The NIH UNI Study: Urea Cycle Disorders, Nutrition and Immunity

NCT01421888
Conditions
Argininosuccinic Aciduria, Carbamoyl-Phosphate Synthase I Deficiency, Citrullinemia, Ornithine Carbamoyltransferase Deficiency, Hyperargininemia, N-Acetylglutamate Synthase Deficiency
Interventions
Not listed
Lead sponsor
National Human Genome Research Institute (NHGRI)
NIH
Eligibility
2 Years to 99 Years
Enrollment
4 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2013
U.S. locations
1
States / cities
Bethesda, Maryland
Conditions
Influenza, Orthomyxoviridae Infections
Interventions
Monovalent subvirion H5N1 influenza vaccine, Physiological saline
Biological
Lead sponsor
Sanofi
Industry
Eligibility
18 Years to 40 Years
Enrollment
375 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2010
U.S. locations
6
States / cities
San Diego, California • South Miami, Florida • Springfield, Missouri + 2 more
Completed Not applicable Interventional Accepts healthy volunteers

Galactooligosaccharide, Immune Strength, and Digestive Health

NCT01137760
Conditions
Healthy
Interventions
Sucrose, Galactooligosaccharide
Dietary Supplement
Lead sponsor
University of Florida
Other
Eligibility
18 Years and older
Enrollment
427 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2010
U.S. locations
1
States / cities
Gainesville, Florida
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Single-ascending-dose Study of the Safety and Immunogenicity of NasoVAX

NCT03232567
Conditions
Influenza
Interventions
NasoVAX
Biological
Lead sponsor
Altimmune, Inc.
Industry
Eligibility
18 Years to 49 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
1
States / cities
Rockville, Maryland
Conditions
HIV Infections, Influenza
Interventions
Cold-adapted live attenuated influenza vaccine (FluMist), Inactivated influenza vaccine (IAIV)
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
5 Years to 17 Years
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 2006
U.S. locations
59
States / cities
Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 42 more
Conditions
Influenza
Interventions
Peramivir, Placebo Comparator
Drug
Lead sponsor
BioCryst Pharmaceuticals
Industry
Eligibility
12 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010
U.S. locations
96
States / cities
Birmingham, Alabama • Hot Springs, Arkansas • Jonesboro, Arkansas + 93 more
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Safety and Immunogenicity of Flublok Quadrivalent vs IIV4 in Adults 18-49 Years of Age

NCT02290509
Conditions
Influenza
Interventions
Flublok Quadrivalent, Inactivated Influenza Vaccine (IIV4)
Biological
Lead sponsor
Protein Sciences Corporation
Industry
Eligibility
18 Years to 49 Years
Enrollment
1,350 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2015
U.S. locations
10
States / cities
Sacramento, California • Coral Gables, Florida • Savannah, Georgia + 7 more
Conditions
Influenza A Virus, H5N1 Subtype
Interventions
VRC-AVIDNA036-00-VP, Monovalent Influenza Subunit Virion (Inactive H5N1) Vaccine
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 60 Years
Enrollment
64 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
1
States / cities
Bethesda, Maryland
Conditions
Influenza
Interventions
Oseltamivir, Placebo
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
1 Year and older
Enrollment
477 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
34
States / cities
Birmingham, Alabama • Little Rock, Arkansas • Stanford, California + 28 more
Conditions
Influenza
Interventions
MF59-eH1N1_f
Biological
Lead sponsor
Novartis
Industry
Eligibility
18 Years and older
Enrollment
2,719 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2010
U.S. locations
20
States / cities
Miami, Florida • Lenexa, Kansas • Omaha, Nebraska + 16 more
Completed Not applicable Interventional Results available

The Respiratory Protection Effectiveness Clinical Trial

NCT01249625
Conditions
Influenza, Respiratory Syncytial Viruses, Paramyxoviridae Infections, Coronavirus, Rhinovirus
Interventions
N95 Respirator, Medical/surgical mask
Device
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years to 100 Years
Enrollment
2,862 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2018
U.S. locations
7
States / cities
Aurora, Colorado • Denver, Colorado • Washington D.C., District of Columbia + 3 more